This combination medication contains Voglibose 0.2mg, Gliclazide 80mg, and Metformin Hydrochloride 500mg, designed for effective management of type 2 diabetes mellitus. Voglibose helps delay glucose absorption from the intestines, controlling post-meal blood sugar spikes. Gliclazide stimulates insulin secretion from pancreatic beta cells, reducing fasting and postprandial glucose levels. Metformin Hydrochloride improves insulin sensitivity, reduces hepatic glucose production, and enhances peripheral glucose uptake. Together, these three agents provide comprehensive glycemic control, making it suitable for patients whose blood sugar is not adequately controlled with diet, exercise, or monotherapy. This formulation is particularly effective in reducing both fasting and postprandial hyperglycemia, while also offering cardiovascular benefits associated with Gliclazide and Metformin.
